Arcutis acquires privately-held biotech Ducentis BioTherapeutics

Sep. 07, 2022 6:09 PM ETArcutis Biotherapeutics, Inc. (ARQT)By: Anuron Mitra, SA News Editor
  • Arcutis Biotherapeutics (NASDAQ:ARQT) on Wednesday said it would acquire Ducentis BioTherapeutics, a privately-held, preclinical-stage biotech developing therapies for inflammation autoimmune diseases.
  • As per the share purchase agreement, Arcutis (ARQT) will acquire Ducentis' shares for an upfront cash payment of about $16M

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.